EpiCast Report: Seasonal Influenza Vaccines - Epidemiology Forecast to 2022

Jan. 10, 2013 - PRLog -- US demand for influenza vaccines will remain high in the coming decade, following a post-flu pandemic spike, predicts business intelligence provider GlobalData.

According to the company’s latest epidemiology report*, seasonal influenza vaccine demand will increase from the 142 million expected for 2012 to 158 million in 2022, representing an Annual Growth Rate (AGR) of 1.2%.

After the H1N1 (originally named ‘swine flu’) pandemic claimed thousands of lives across the US in 2009, the number of those vaccinated annually climbed significantly – from 24% in 2007 to 41% in 2010 for citizens aged 5-64 years – according to the US Centers for Disease Control and Prevention (CDC).

The new GlobalData reports says that the primary driver for the predicted growth in influenza vaccine demand will be a general increase in the US population and the corresponding rise in those classed as high-risk, such as the elderly or those with preexisting conditions.

Of the nine major markets explored in the report (the US, Japan, India, China, and the top five European economies), India is expected to exhibit the greatest surge in vaccine demand over the next 10 years, climbing at a AGR of 2.1%. However, despite this relative growth, GlobalData estimates that the percentage of influenza-vaccinated citizens in the country will total a meager 1.7% of the population by 2022.

For Sample Pages, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/RequestSamplePages.aspx?CompanyID=prlog&ID=Seasonal-Influenza-Vaccines-Epidemiology-Forecast-to-2022&ReportType=Industry_Report&title=Pharmaceuticals_and_Healthcare&CompanyID=prlog

The Seasonal Influenza Vaccines EpiCast Report provides an overview of risk factors for seasonal influenza and global trends for seasonal influenza vaccination coverage in the US, France, Germany, Italy, Spain, the UK, Japan, India, and China.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData.

The facts of this report are believed to be correct at the time of publication but cannot be guaranteed.

Please note that the findings, conclusions and recommendations that GlobalData delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such GlobalData can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.

For further details, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/Report.aspx?ID=Seasonal-Influenza-Vaccines-Epidemiology-Forecast-to-2022&CompanyID=prlog

Visit our report store:

http://www.globaldata.com/reportstore

For more details contact:pressreleases@globaldata.com


North America:          +1 646 395 5477

Europe:          +44 207 753 4299

         +44 1204 543 533
Asia Pacific:          +91 40 6616 6782